You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR PARICALCITOL

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for paricalcitol

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00048438 ↗	Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)	Completed	Abbott	Phase 3	2002-02-01	The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
NCT00048451 ↗	Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)	Completed	Abbott	Phase 3	2002-02-01	The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
NCT00048516 ↗	Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)	Completed	Abbott	Phase 3	2002-02-01	The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
NCT00064376 ↗	Paricalcitol in Treating Patients With Myelodysplastic Syndrome	Completed	Abbott	Phase 2	2003-05-01	RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for paricalcitol

Condition Name

Chart
Table

Condition Name for paricalcitol
Intervention	Trials
Secondary Hyperparathyroidism	22
Chronic Kidney Disease	21
Pancreatic Cancer	8
Hemodialysis	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for paricalcitol
Intervention	Trials
Kidney Diseases	50
Renal Insufficiency, Chronic	43
Hyperparathyroidism	33
Hyperparathyroidism, Secondary	32
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for paricalcitol

Trials by Country

Map
Table

Trials by Country for paricalcitol
Location	Trials
United States	205
Spain	18
Italy	12
Poland	7
Malaysia	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for paricalcitol
Location	Trials
California	14
New York	13
Pennsylvania	12
Texas	12
Illinois	10
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for paricalcitol

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for paricalcitol
Clinical Trial Phase	Trials
Phase 4	25
Phase 3	21
Phase 2	21
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for paricalcitol
Clinical Trial Phase	Trials
Completed	62
Terminated	11
Recruiting	7
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for paricalcitol

Sponsor Name

Chart
Table

Sponsor Name for paricalcitol
Sponsor	Trials
Abbott	36
AbbVie (prior sponsor, Abbott)	6
National Cancer Institute (NCI)	5
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for paricalcitol
Sponsor	Trials
Other	105
Industry	64
NIH	7
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.